Skip to content
Kalpvruksh Markets
Offline Log in

REMUSNSEOffline

REMUS PHARMACEUTICAL · INE0O5T01011 · Small Cap · #1530
839.80+20.25 (+2.47%)last close · 05 Nov 2026
Prev close
819.55
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹819 cr

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

REMUS is a Small Cap company, #1530 by market cap.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • no promoter pledge
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹819 cr
Rank
#1530
Cap band
Small Cap
Nearest cut-off — Mid / Small
−97.60% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.7×
median 3,250
Delivered
2,300
Of volume
85%

Price & trend

Price & trend

Not enough price historyFigures need 60 sessions of NSE prices.

Ownership

Who owns the company

% of all shares, by quarter

GroupSep 25Mar 26Sep 26
Promoters70.9%71.0%71.0%
FPI5.0%5.3%5.1%
Mutual funds———
Other DII0.8%0.8%0.4%
Individuals18.8%18.5%18.4%
Others4.5%4.4%5.1%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Sep 25 noneMar 26 noneSep 26 none

Holders

Sep 26

All shareholders
2,092
Individuals
1,818

Which funds bought and sold

No fund holds this companyNo Indian mutual fund disclosed a position at the last quarter end.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 50 of 92 disclosures
0 selected
02 Jan 2026Alkaben Dipakkumar ShahPromoter GroupBuy2,600₹0.18 cr0.02%Market Purchase
19 Dec 2025ARPIT DEEPAKKUMAR SHAHPromotersBuy1,200₹0.09 cr17.66%Market Purchase
19 Dec 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy500₹0.04 cr0.92%Market Purchase
11 Dec 2025DHRUVALBEN V SHAHPromoter GroupBuy500₹0.04 cr0.01%Market Purchase
10 Dec 2025Vinodkumar Gandalal ShahPromoter GroupBuy500₹0.04 cr0.06%Market Purchase
30 Sept 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy200₹0.01 cr0.92%Market Purchase
22 Sept 2025ROMA VINODBHAI SHAHPromotersBuy3,000₹0.24 cr17.21%Market Purchase
07 Aug 2025DHRUVALBEN V SHAHPromoter GroupBuy200₹0.02 cr0.00%Market Purchase
03 Feb 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy400₹0.08 cr0.91%Market Purchase
03 Feb 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy200₹0.04 cr0.91%Market Purchase
07 Jan 2025Vinodkumar Gandalal ShahPromoter GroupBuy50₹0.01 cr0.05%Market Purchase
06 Jan 2025Vinodkumar Gandalal ShahPromoter GroupBuy50₹0.01 cr0.05%Market Purchase
06 Jan 2025Vinodkumar Gandalal ShahPromoter GroupBuy50₹0.01 cr0.05%Market Purchase
03 Jan 2025Vinodkumar Gandalal ShahPromoter GroupSell50₹0.01 cr0.05%Market Sale
30 Dec 2024Vinodkumar Gandalal ShahPromoter GroupBuy50₹0.01 cr0.05%Market Purchase

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Remus Pharmaceuticals Limited has submitted to the Exchange Outcome of Board Meeting held on November 03, 2026
    03 Nov 2026
  • Board outcome
    Outcome of Board Meeting-XBRL REMUS PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 03-Nov-2026 for Dividend
    03 Nov 2026
  • Board outcome
    Remus Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026.
    03 Sept 2026
  • Scheme / acquisition
    Acquisition of 'to be incorporated companies'-XBRL REMUS PHARMACEUTICALS LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies
    03 Sept 2026
  • Board outcome
    Remus Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 23, 2026.
    24 Jun 2026
  • Board outcome
    Remus Pharmaceuticals Limited has submitted to the Exchange the outcome of Board Meeting held on May 20, 2026
    20 May 2026
  • Bulk deal: SELL
    63,900 at ₹830.19 — BLUE LOTUS CAPITAL MULTI BAGGER FUND II
    07 Aug 2026

Latest shown; 9 in six months on all disclosures.

REMUS: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
RecentDividend₹0.5Final22 Sept 202622 Sept 2026
EarlierDividend₹0.5Interim14 Nov 202514 Nov 2025
EarlierDividend₹0.5Final18 Sept 202518 Sept 2025
EarlierBonus1:1—04 Jul 202504 Jul 2025
EarlierDividend₹1Interim19 Nov 202420 Nov 2024
EarlierBonus3:1—06 Jun 202406 Jun 2024
EarlierDividend₹4Interim02 May 202402 May 2024
EarlierDividend₹2Interim27 Oct 202328 Oct 2023
EarlierDividend₹2Final15 Sept 202315 Sept 2023

9 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.